St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
Hepatocellular carcinoma (HCC) is a type of liver cancer that usually affects people whose livers have been under a lot of stress for a long time. This stress could be caused by hepatitis B or C, metabolic diseases, or use of certain drugs for a long time. These drugs include:
Hepatocellular carcinoma is rare in children, especially those younger than 5. Less than 1 child in 1 million is diagnosed with this disease. It is usually diagnosed in children ages 12–14.
Find out more about hepatocellular carcinoma on the Together by St. Jude™ online resource.
The main treatment for hepatocellular carcinoma is surgery. It could require a liver transplant if the tumor involves the whole liver. Chemotherapy may be used to shrink the tumor to make it easier to remove.
St. Jude offers clinical trials and cancer research studies for children, teens, and young adults with liver cancer. Learn more about clinical trials at St. Jude.
Study goal:
In Part 1 of this study, we will see if sorafenib, cyclophosphamide, bevacizumab, and atezolizumab can be given safely together without causing serious side effects. Part 2 of the study will find out how well these medicines work in hepatocellular carcinoma, fibrolamellar carcinoma, desmoplastic small round cell tumors, and malignant rhabdoid tumors.
Age:
1-30 years old
Study goal:
The main purpose of this study is to find out how well the medicine tegavivint works to help children, teens, and young adults with certain recurrent or refractory solid tumors.
Age:
12 months to 30 years
St. Jude Children’s Research Hospital provides the highest quality of care for patients with pediatric liver cancer:
We are consistently ranked among the best childhood cancer centers in the nation by US News & World Report.
We have created an environment where children can be children and families can be together.
We lead more clinical trials for childhood cancer than any other hospital in the U.S.
St. Jude is the only National Cancer Institute–designated Comprehensive Cancer Center just for children. A Comprehensive Cancer Center meets rigorous standards for research that develops new and better approaches to prevent, diagnose, and treat cancer.
The nurse-to-patient ratio at St. Jude is about 1:3 in hematology and oncology and 1:1 in the Intensive Care Unit.
Patients may be able to get expert, compassionate care and treatment closer to their homes through the St. Jude Affiliate Program.
Patients accepted to St. Jude must have a disease we treat and must be referred by a physician or other qualified medical professional. We accept most patients based on their ability to enroll in an open clinical trial.
Call: 1-888-226-4343 (toll-free) or 901-595-4055 (local) | Fax: 901-595-4011 | Email: referralinfo@stjude.org | 24-hour pager: 1-800-349-4334
The solid tumor coordinator is dedicated to helping you seek treatment or refer a patient.
Solid Tumor Coordinator